Iridex Meets Nasdaq Listing Standards Again
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 09 2025
0mins
Should l Buy IRIX?
Compliance with Nasdaq: Iridex Corporation has received formal notice from Nasdaq confirming its compliance with continued listing requirements.
Minimum Stockholders' Equity: As of August 27, Iridex satisfied the minimum stockholders' equity requirement of $2.5 million under Nasdaq Listing Rule 5550(b).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRIX
About IRIX
IRIDEX Corporation is an ophthalmic medical technology company. The Company is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Iridex's MicroPulse Technology Effectively Lowers Intraocular Pressure in Glaucoma Patients
- Clinical Study Results: An independent study at the University Eye Clinic Maastricht shows that retreatment with MicroPulse laser treatment (MicroPulse TLT) reduces intraocular pressure (IOP) by 25% to 35% in glaucoma patients, demonstrating the technology's effectiveness and safety in glaucoma management.
- Treatment Flexibility: The study involved 76 eyes, with retreatment timing varying from approximately 4 months to over 28 months, showcasing the individualized management capabilities of the technology, allowing for flexible treatment adjustments based on patient responses.
- Success Rate of Repeat Treatments: Results indicate that patients who initially benefited from treatment have higher long-term success rates upon retreatment, aiding clinicians in better identifying candidates for retreatment and optimizing glaucoma management strategies.
- Company Strategic Commitment: Iridex CEO Patrick Mercer stated that the findings further validate MicroPulse TLT as a valuable non-incisional option, reflecting the company's strong commitment to advancing clinical evidence and supporting ophthalmologists in delivering durable outcomes for their patients.
See More
Iridex Publishes Study on Thermal Dynamics of Laser Treatments for Glaucoma
- Research Findings: Iridex's newly published study provides the first quantitative comparison of thermal tissue effects between CW-TSCPC and MicroPulse TLT, revealing that CW-TSCPC creates a 2 mm thermal zone exceeding 100°C for 2.2 seconds, indicating potential risks in glaucoma treatment.
- Technical Advantages: MicroPulse TLT generates a smaller thermal zone of 0.6-1.2 mm with peak temperatures below 100°C, demonstrating its safety and uniform heat distribution, which may offer a safer option for earlier interventions.
- Clinical Significance: The study underscores the thermal continuum between the two techniques, suggesting that with further optimization, they could serve complementary roles in glaucoma management, enhancing treatment diversity.
- Company Commitment: Iridex CEO Patrick Mercer highlighted that this research reflects the company's commitment to evidence-based innovation in glaucoma care, aiming to improve treatment outcomes through a deeper understanding of laser interactions with ocular tissues.
See More
Iridex Publishes Study on Thermal Dynamics of Laser Treatments for Glaucoma
- Research Findings: Iridex's newly published study quantifies the thermal effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) versus MicroPulse laser therapy, revealing that CW-TSCPC creates a 2mm thermal zone exceeding 100°C for approximately 2.2 seconds, highlighting distinct thermal dynamics in glaucoma treatment.
- Technology Optimization: The study indicates that MicroPulse TLT generates a smaller thermal zone (0.6-1.2mm) with peak temperatures below 100°C, offering a more uniform heat distribution, which may provide new treatment avenues for early intervention in glaucoma cases.
- Clinical Significance: Dr. Grippo emphasizes that analyzing heat behavior through computational models allows for a reinterpretation of existing clinical evidence, providing insights that could enhance the optimization and safety of both laser techniques, thereby creating broader clinical opportunities in glaucoma management.
- Company Commitment: Iridex CEO Mercer states that the study underscores the company's commitment to evidence-based innovation in glaucoma care, aiming to improve treatment optimization and safety by deepening the understanding of how laser technologies interact with ocular tissues.
See More
Iridex Corporation to Present at Sidoti Year-End Virtual Investor Conference
- Conference Participation: Iridex Corporation plans to present at the Sidoti Year-End Virtual Investor Conference on December 11 at 10:45 AM ET, showcasing its innovative laser medical systems for glaucoma and retinal disease treatment.
- Technological Advantage: The company leverages its proprietary MicroPulse® technology to provide safe and effective laser treatment options that minimize tissue damage, thereby reinforcing its leadership position in the ophthalmology market.
- Global Market Reach: Iridex's products are sold in over 100 countries through a direct sales force and independent distributor network, demonstrating its strong international market penetration to meet the growing global demand for ophthalmic treatment devices.
- Investor Relations Transparency: Investors can access live and archived webcasts of the presentation via the “Investors” section of the company’s website, reflecting Iridex's commitment to investor communication aimed at enhancing market trust and investor engagement.
See More
LightPath Technologies Shares Rise 7%; Check Out 20 Stocks Making Moves in Premarket Trading
LightPath Technologies Performance: LightPath Technologies Inc. shares rose 6.8% in pre-market trading after reporting a quarterly loss of 7 cents per share, which was better than the expected 9-cent loss, alongside revenue of $15.05 million exceeding estimates.
Notable Gainers: Salarius Pharmaceuticals surged 170% after announcing pricing for its public offering, while Kandal M Venture and Amaze Holdings also saw significant pre-market gains of 70.4% and 68.4%, respectively.
Significant Losers: MSP Recovery Inc. dropped 18.2% in pre-market trading following a previous surge, with other notable declines including Aspire Biopharma and Rain Enhancement Technologies, which fell 16.5% and 14.3%, respectively.
Market Overview: The article provides a snapshot of various stocks moving in pre-market trading, highlighting both gainers and losers, along with specific percentage changes in their share prices.
See More
Iridex Meets Nasdaq Listing Requirements Again
Compliance with Nasdaq: Iridex has received confirmation from Nasdaq that it has regained compliance with continued listing standards after previously being notified of non-compliance regarding stockholders’ equity.
Financial Performance: The company met the $2.5 million minimum stockholders’ equity requirement based on its Q2 report, which showed a 14% sequential revenue increase, and is targeting profitability in 2025.
See More
Iridex's MicroPulse Technology Effectively Lowers Intraocular Pressure in Glaucoma Patients
- Clinical Study Results: An independent study at the University Eye Clinic Maastricht shows that retreatment with MicroPulse laser treatment (MicroPulse TLT) reduces intraocular pressure (IOP) by 25% to 35% in glaucoma patients, demonstrating the technology's effectiveness and safety in glaucoma management.
- Treatment Flexibility: The study involved 76 eyes, with retreatment timing varying from approximately 4 months to over 28 months, showcasing the individualized management capabilities of the technology, allowing for flexible treatment adjustments based on patient responses.
- Success Rate of Repeat Treatments: Results indicate that patients who initially benefited from treatment have higher long-term success rates upon retreatment, aiding clinicians in better identifying candidates for retreatment and optimizing glaucoma management strategies.
- Company Strategic Commitment: Iridex CEO Patrick Mercer stated that the findings further validate MicroPulse TLT as a valuable non-incisional option, reflecting the company's strong commitment to advancing clinical evidence and supporting ophthalmologists in delivering durable outcomes for their patients.
See More
Iridex Publishes Study on Thermal Dynamics of Laser Treatments for Glaucoma
- Research Findings: Iridex's newly published study provides the first quantitative comparison of thermal tissue effects between CW-TSCPC and MicroPulse TLT, revealing that CW-TSCPC creates a 2 mm thermal zone exceeding 100°C for 2.2 seconds, indicating potential risks in glaucoma treatment.
- Technical Advantages: MicroPulse TLT generates a smaller thermal zone of 0.6-1.2 mm with peak temperatures below 100°C, demonstrating its safety and uniform heat distribution, which may offer a safer option for earlier interventions.
- Clinical Significance: The study underscores the thermal continuum between the two techniques, suggesting that with further optimization, they could serve complementary roles in glaucoma management, enhancing treatment diversity.
- Company Commitment: Iridex CEO Patrick Mercer highlighted that this research reflects the company's commitment to evidence-based innovation in glaucoma care, aiming to improve treatment outcomes through a deeper understanding of laser interactions with ocular tissues.
See More
Iridex Publishes Study on Thermal Dynamics of Laser Treatments for Glaucoma
- Research Findings: Iridex's newly published study quantifies the thermal effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) versus MicroPulse laser therapy, revealing that CW-TSCPC creates a 2mm thermal zone exceeding 100°C for approximately 2.2 seconds, highlighting distinct thermal dynamics in glaucoma treatment.
- Technology Optimization: The study indicates that MicroPulse TLT generates a smaller thermal zone (0.6-1.2mm) with peak temperatures below 100°C, offering a more uniform heat distribution, which may provide new treatment avenues for early intervention in glaucoma cases.
- Clinical Significance: Dr. Grippo emphasizes that analyzing heat behavior through computational models allows for a reinterpretation of existing clinical evidence, providing insights that could enhance the optimization and safety of both laser techniques, thereby creating broader clinical opportunities in glaucoma management.
- Company Commitment: Iridex CEO Mercer states that the study underscores the company's commitment to evidence-based innovation in glaucoma care, aiming to improve treatment optimization and safety by deepening the understanding of how laser technologies interact with ocular tissues.
See More
Iridex Corporation to Present at Sidoti Year-End Virtual Investor Conference
- Conference Participation: Iridex Corporation plans to present at the Sidoti Year-End Virtual Investor Conference on December 11 at 10:45 AM ET, showcasing its innovative laser medical systems for glaucoma and retinal disease treatment.
- Technological Advantage: The company leverages its proprietary MicroPulse® technology to provide safe and effective laser treatment options that minimize tissue damage, thereby reinforcing its leadership position in the ophthalmology market.
- Global Market Reach: Iridex's products are sold in over 100 countries through a direct sales force and independent distributor network, demonstrating its strong international market penetration to meet the growing global demand for ophthalmic treatment devices.
- Investor Relations Transparency: Investors can access live and archived webcasts of the presentation via the “Investors” section of the company’s website, reflecting Iridex's commitment to investor communication aimed at enhancing market trust and investor engagement.
See More
LightPath Technologies Shares Rise 7%; Check Out 20 Stocks Making Moves in Premarket Trading
LightPath Technologies Performance: LightPath Technologies Inc. shares rose 6.8% in pre-market trading after reporting a quarterly loss of 7 cents per share, which was better than the expected 9-cent loss, alongside revenue of $15.05 million exceeding estimates.
Notable Gainers: Salarius Pharmaceuticals surged 170% after announcing pricing for its public offering, while Kandal M Venture and Amaze Holdings also saw significant pre-market gains of 70.4% and 68.4%, respectively.
Significant Losers: MSP Recovery Inc. dropped 18.2% in pre-market trading following a previous surge, with other notable declines including Aspire Biopharma and Rain Enhancement Technologies, which fell 16.5% and 14.3%, respectively.
Market Overview: The article provides a snapshot of various stocks moving in pre-market trading, highlighting both gainers and losers, along with specific percentage changes in their share prices.
See More
Iridex Meets Nasdaq Listing Requirements Again
Compliance with Nasdaq: Iridex has received confirmation from Nasdaq that it has regained compliance with continued listing standards after previously being notified of non-compliance regarding stockholders’ equity.
Financial Performance: The company met the $2.5 million minimum stockholders’ equity requirement based on its Q2 report, which showed a 14% sequential revenue increase, and is targeting profitability in 2025.
See More
